![<?echo $_SERVER['SERVER_NAME'];?>](/template/twentyseventeen/skin/images/header.jpg)
January 2012 9th - 12th, the 30th Annual JP Morgan Healthcare held in San Francisco, the meeting attracted about 8,000 investors and relevant company representatives. At the meeting, the presidents and CEOs of major companies respectively explained to investors their new year's development plans and new products for listing.
On the first day of the meeting, Agilent officials once again emphasized that the company plans to further penetrate the scientific research market. The current scientific market business accounted for 8% of Agilent's total business. At the same time, it also stated that the company’s goal is to continue its expansion in the Asia Pacific region.
Currently, Asia Pacific revenues account for 39% of Agilent's total revenue, compared with 37% in the Americas and 32% in Europe; and the area's life sciences revenue accounts for about 31% of Agilent's total life sciences revenue. According to Nick Roelofs, president of Agilent's Life Sciences Division, "As China and India continue to invest in life sciences, Agilent will also increase investment in these areas, including hiring more people. Currently, about 17% of Agilent life sciences employees are in Asia Pacific. District work."
Nick Roelofs also stated that “China is currently the second largest market for Agilent’s life sciences business. In the fourth quarter of 2011, Agilent’s life sciences business achieved a 29% growth in China while India achieved a 15% growth. the two regions have also taken relevant initiatives, such as the expansion of the application of life science research center in Bangalore, India, is under construction in Penang, Malaysia and other PCR instrument development team. "
Speaking of the company's end market, Nick Roelofs said, "He thinks the academic/government sector will continue to be stable because the European and U.S. governments seem reluctant to cut science funds. In the pharmaceutical/biotech market, the outlook is not clear. Because the department is still reluctant to spend money on tools and instruments."
On the first day of the meeting, Agilent officials once again emphasized that the company plans to further penetrate the scientific research market. The current scientific market business accounted for 8% of Agilent's total business. At the same time, it also stated that the company’s goal is to continue its expansion in the Asia Pacific region.
Currently, Asia Pacific revenues account for 39% of Agilent's total revenue, compared with 37% in the Americas and 32% in Europe; and the area's life sciences revenue accounts for about 31% of Agilent's total life sciences revenue. According to Nick Roelofs, president of Agilent's Life Sciences Division, "As China and India continue to invest in life sciences, Agilent will also increase investment in these areas, including hiring more people. Currently, about 17% of Agilent life sciences employees are in Asia Pacific. District work."
Nick Roelofs also stated that “China is currently the second largest market for Agilent’s life sciences business. In the fourth quarter of 2011, Agilent’s life sciences business achieved a 29% growth in China while India achieved a 15% growth. the two regions have also taken relevant initiatives, such as the expansion of the application of life science research center in Bangalore, India, is under construction in Penang, Malaysia and other PCR instrument development team. "
Speaking of the company's end market, Nick Roelofs said, "He thinks the academic/government sector will continue to be stable because the European and U.S. governments seem reluctant to cut science funds. In the pharmaceutical/biotech market, the outlook is not clear. Because the department is still reluctant to spend money on tools and instruments."
Road Maintenance Equipment,Road Cleaning Machine,High Pressure Cleaning Machine,Highway Guardrail Cleaning Truck
Henan Lukewei Road Machinery Manufacturing Co.,Ltd , https://www.lkwmachinery.com